In December 2016 the Czech Drug Authority announced that the Soratinex regimen
qualifies to be designated a ’medical device’ under EU legislation. Our application for
European ’CE ’ standard certification, which is obligatory in order to market the
treatment as such, is pending. Once granted, FRANKL Pharma will push for Soratinex
to be prescribed on the NHS.